Wooil Kwon

Dr. Wooil Kwon


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SSSimeon Springer
Simeon Springer
DMDavid L. Masica
David L. Masica
MMMarco Dal Molin
Marco Dal Molin
CDChristopher Douville
Christopher Douville
CTChristopher J. Thoburn
Christopher J. Thoburn
ALAnne Marie Lennon
Anne Marie Lennon
Molecular and clinical markers outperform current clinical and imaging criteria for the diagnosis and management of patients with pancreatic cysts.

1 February 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YHYoungmin Han
Youngmin Han
HLHongeun Lee
Hongeun Lee
JKJae Seung Kang
Jae Seung Kang
JKJae Ri Kim
Jae Ri Kim
HKHyeong Seok Kim
Hyeong Seok Kim
JJJin-Young Jang
Jin-Young Jang

20 August 2022 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
SPStefano Partelli
Stefano Partelli
Sara MassironiSara Massironi
Sara Massironi
AZAlessandro Zerbi
Alessandro Zerbi
PNPatricia Niccoli
Patricia Niccoli
WKWooil Kwon
Wooil Kwon
MFMassimo Falconi
Massimo Falconi
The incidence of non-functioning pancreatic neuroendocrine neoplasms (NF-PanNENs) has increased recently1. Traditionally, surgery has been the treatment of choice for localized NF-PanNENs, although evidence has emerged that active surveillance could be advocated for most asymptomatic tumours no larger than 2 cm2–7. However, the practice of active surveillance varies considerably and, contrary to current recommendations8–10, many patients still undergo surgical resection11–13.

26 May 2020 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
WKWooil Kwon
Wooil Kwon
HKHongbeom Kim
Hongbeom Kim
YHY. Han
Y. Han
YHY. J. Hwang
Y. J. Hwang
SKS G Kim
S G Kim
JJJ.‐Y. Jang
J.‐Y. Jang
Background In gallbladder cancer, stage T2 is subdivided by tumour location into lesions on the peritoneal side (T2a) or hepatic side (T2b). For tumours on the peritoneal side (T2a), it has been suggested that liver resection may be omitted without compromising the prognosis. However, data to validate this argument are lacking. This study aimed to investigate the prognostic value of tumour location in T2 gallbladder cancer, and to clarify the adequate extent of surgical resection. Methods Clinical data from patients who underwent surgery for gallbladder cancer were collected from 14 hospitals in Korea, Japan, Chile and the USA. Survival and risk factor analyses were conducted. Results Data from 937 patients were available for evaluation. The overall 5‐year disease‐free survival rate was 70·6 per cent, 74·5 per cent for those with T2a and 65·5 per cent among those with T2b tumours (P = 0·028). Regarding liver resection, extended cholecystectomy was associated with a better 5‐year disease‐free survival rate than simple cholecystectomy (73·0 versus 61·5 per cent; P = 0·012). The 5‐year disease‐free survival rate was marginally better for extended than simple cholecystectomy in both T2a (76·5 versus 66·1 per cent; P = 0·094) and T2b (68·2 versus 56·2 per cent; P = 0·084) disease. Five‐year disease‐free survival rates were similar for extended cholecystectomies including liver wedge resection versus segment IVb/V segmentectomy (74·1 versus 71·5 per cent; P = 0·720). In multivariable analysis, independent risk factors for recurrence were presence of symptoms (hazard ratio (HR) 1·52; P = 0·002), R1 resection (HR 1·96; P = 0·004) and N1/N2 status (N1: HR 3·40, P < 0·001; N2: HR 9·56, P < 0·001). Among recurrences, 70·8 per cent were metastatic. Conclusion Tumour location was not an independent prognostic factor in T2 gallbladder cancer. Extended cholecystectomy was marginally superior to simple cholecystectomy. A radical operation should include liver resection and adequate node dissection.

1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JKJae Ri Kim
Jae Ri Kim
KLKyoung Bun Lee
Kyoung Bun Lee
WKWooil Kwon
Wooil Kwon
EKEunjung Kim
Eunjung Kim
SKSun-Whe Kim
Sun-Whe Kim
JJJin-Young Jang
Jin-Young Jang
Kim JR, et al. J Korean Med Sci. 2018 Sep;33(42):e266. https://doi.org/10.3346/jkms.2018.33.e266

1 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HKHongbeom Kim
Hongbeom Kim
KKKyung Nam Kang
Kyung Nam Kang
YSYong Sung Shin
Yong Sung Shin
YBYoonhyeong Byun
Yoonhyeong Byun
YHYoungmin Han
Youngmin Han
JJJin-Young Jang
Jin-Young Jang
A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC.